welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
UT Researcher, With CureDuchenne Support, Launches Company to Treat DMD Using CRISPR/Cas9 TechnologyEric Olson, a molecular biologist, has s...
-
New lab technology could reveal treatments for muscle-wasting diseaseResearchers from Queen Mary University o...
-
From Flask to Vat: The Challenges of Scaling Up Gene TherapyOver the past two decades, gene therapy ...
-
Single CRISPR Treatment Provides Long-Term Benefits in MiceResearchers at Duke University have show...
-
Development of Novel Micro-dystrophins with Enhanced FunctionalityGene therapies using adeno-associated vi...
-
Personalized gene and cell therapy for Duchenne Muscular DystrophyDystrophinopathies are diseases caused b...
-
Exon Skipping Explained from Sarepta Therapeuticshttps://player.vimeo.com/video/238953537...
